Burning Rock Biotech Ltd - Asset Resilience Ratio
Burning Rock Biotech Ltd (BNR) has an Asset Resilience Ratio of 0.72% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Burning Rock Biotech Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Burning Rock Biotech Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Burning Rock Biotech Ltd.
Liquid Assets Composition Over Time
This chart breaks down Burning Rock Biotech Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore BNR long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.14 Million | 0.72% |
| Total Liquid Assets | $6.14 Million | 0.72% |
Asset Resilience Insights
- Limited Liquidity: Burning Rock Biotech Ltd maintains only 0.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Burning Rock Biotech Ltd Industry Peers by Asset Resilience Ratio
Compare Burning Rock Biotech Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Chemclin Diagnostics Co. Ltd. A
SHG:688468 |
Diagnostics & Research | 15.34% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Scope Fluidics SA
WAR:SCP |
Diagnostics & Research | 16.51% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Annual Asset Resilience Ratio for Burning Rock Biotech Ltd (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Burning Rock Biotech Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.69% | $6.14 Million | $885.30 Million | -0.60pp |
| 2023-12-31 | 1.29% | $13.40 Million | $1.04 Billion | +1.16pp |
| 2022-12-31 | 0.13% | $2.09 Million | $1.59 Billion | -2.67pp |
| 2021-12-31 | 2.80% | $63.76 Million | $2.28 Billion | -10.80pp |
| 2020-12-31 | 13.60% | $362.13 Million | $2.66 Billion | -23.45pp |
| 2019-12-31 | 37.05% | $313.99 Million | $847.56 Million | +27.18pp |
| 2018-12-31 | 9.87% | $36.79 Million | $372.67 Million | -23.90pp |
| 2017-12-31 | 33.77% | $135.21 Million | $400.33 Million | -- |
About Burning Rock Biotech Ltd
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction test… Read more